Similar findings were noted in a long-term analysis of the CABG cohort of the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) trial, in which a lack of aspirin prescription at hospital discharge was identified as the strongest predictor of death at 4 years (hazard ratio [HR], With several trials featuring varied treatment protocols hav- ing been published in the literature, Fremes et al21 reviewed the impact of antiplatelet and anticoagulant therapy on vein graft patency in a meta-analysis of 17 randomized trials. Summarizing the data, the authors reported that aspirin sig- nificantly reduced the odds of graft occlusion compared with placebo (aspirin with or without dipyridamole versus placebo: damole with aspirin provided no additional benefit compared with aspirin alone (aspirin plus dipyridamole versus aspirin further noted that a low (100 mg) to medium (325 mg) dose of daily aspirin was more effective and safer than a high dose (975 mg). Although preoperative administration provided no additional benefit, the ideal time for initiation of aspirin appeared to be within 6 hours after CABG. All together, the authors recommended indefinite aspirin use postoperatively in doses of 100 to 325 mg daily. Subsequently, Lim et al22 performed a meta-analysis of 5 randomized, controlled tri- als to compare the efficacy of low-dose (50 100 mg daily) and medium-dose (300 325 mg daily) aspirin therapy after CABG. Compared with low-dose aspirin, there was a trend toward an improvement in graft patency in favor of medium- statistical significance was not achieved, the authors advo- cated for the use of aspirin at a medium dose of 325 mg daily because of its excellent safety profile and minimal increase in cost. 